ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by ALX Oncology Holdings Inc. on June 12, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol ALXO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Three proposals were submitted to a vote of security holders:
- Proposal 1: Election of Three Class I Directors
- Corey Goodman, Ph.D.: Elected with 35,775,363 votes For, 6,616,621 Withheld.
- Jason Lettmann: Elected with 33,828,276 votes For, 8,563,708 Withheld.
- Sophia Randolph, Ph.D.: Elected with 28,671,086 votes For, 13,720,898 Withheld.
- All nominees were elected to serve until the 2027 annual meeting.
- Proposal 2: Advisory Vote on Executive Compensation
- Approved with 40,935,354 votes For, 1,422,239 Against, and 34,391 Abstentions.
- Proposal 3: Ratification of Independent Auditor
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Voting results: 47,698,670 For, 11,338 Against, 2,733 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I Directors (Corey Goodman, Jason Lettmann, Sophia Randolph) through the 2027 annual meeting.
- Confirm the appointment of KPMG LLP as the auditor for the fiscal year ending December 31, 2024.
- Note the significant number of broker non-votes (5,320,757) recorded for the director elections and executive compensation vote.
- Review the company's proxy statement for detailed executive compensation data referenced in Proposal 2.